Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more
Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.27 Billion CNY
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) has total liabilities worth CN¥2.27 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangxi Fushine Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangxi Fushine Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Viad Corp
NYSE:VVI
|
USA | $1.00 Billion |
|
National Beverage Corp
NASDAQ:FIZZ
|
USA | $197.72 Million |
|
Thai Union Group PCL
BK:TU
|
Thailand | ฿106.24 Billion |
|
Hongta Securities Co Ltd
SHG:601236
|
China | CN¥31.73 Billion |
|
Criteo Sa
NASDAQ:CRTO
|
USA | $1.02 Billion |
|
Neuren Pharmaceuticals Limited
PINK:NURPF
|
USA | $7.98 Million |
|
Shanghai Emperor of Cleaning Hi-Tech Co Ltd
SHG:603200
|
China | CN¥548.17 Million |
|
Sichuan Chengfei Integration Technology Corp Ltd
SHE:002190
|
China | CN¥2.57 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangxi Fushine Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.36 Billion | +0.50% |
| 2023-12-31 | CN¥2.35 Billion | -0.92% |
| 2022-12-31 | CN¥2.37 Billion | +34.12% |
| 2021-12-31 | CN¥1.77 Billion | +77.09% |
| 2020-12-31 | CN¥997.93 Million | -6.59% |
| 2019-12-31 | CN¥1.07 Billion | +1.76% |
| 2018-12-31 | CN¥1.05 Billion | +27.60% |
| 2017-12-31 | CN¥822.70 Million | +33.95% |
| 2016-12-31 | CN¥614.20 Million | +48.56% |
| 2015-12-31 | CN¥413.44 Million | +18.44% |
| 2014-12-31 | CN¥349.09 Million | +12.05% |
| 2013-12-31 | CN¥311.55 Million | +6.80% |
| 2012-12-31 | CN¥291.70 Million | +25.71% |
| 2011-12-31 | CN¥232.04 Million | -- |